Google trend - Covishield

Covishield - 10 things to know with detail

• Covishield is the brand name for the COVID-19 vaccine developed by AstraZeneca in collaboration with the University of Oxford.
• The vaccine is based on a viral vector platform that uses a weakened version of a common cold virus (adenovirus) found in chimpanzees to deliver genetic material from the spike protein of the SARS-CoV-2 virus into the body.
• Covishield has been granted emergency use authorization in several countries, including India, the United Kingdom, and European Union countries, for the prevention of COVID-19 in individuals aged 18 and above.
• The vaccine has shown an average efficacy of around 70% in preventing symptomatic COVID-19 infection in clinical trials, although this can vary depending on factors such as age and dosing regimen.
• Covishield is administered as a two-dose regimen, with the second dose given 4 to 12 weeks after the first dose to maximize its effectiveness.
• Common side effects of the Covishield vaccine include pain at the injection site, fatigue, headache, muscle pain, chills, fever, and nausea. These side effects are usually mild to moderate in severity and resolve within a few days.
• The vaccine has been found to be safe and well-tolerated in clinical trials, with rare reports of serious adverse events such as anaphylaxis or blood clots, which are being closely monitored by regulatory authorities.
• Covishield can be stored and transported at standard refrigerator temperatures of 2 to 8 degrees Celsius, making it easier to distribute and administer in various settings.
• The vaccine has been included in the COVAX initiative, a global partnership aimed at ensuring equitable access to COVID-19 vaccines for all countries, particularly low- and middle-income countries.
• Covishield is one of the key vaccines being used in national vaccination campaigns around the world to control the spread of COVID-19 and protect public health.